0NWK Stock Chart & Stats
€0.06
€0.00(0.00%)
At close: 4:00 PM EST
€0.06
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.06 - €0.98
Previous CloseN/A
Volume0.00
Average Volume (3M)19.05K
Market Cap
€386.00M
Enterprise Value€77.01M
Total Cash (Recent Filing)€1.05M
Total Debt (Recent Filing)€7.61M
Price to Earnings (P/E)―
Beta0.77
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding567,668,640
10 Day Avg. Volume21,071
30 Day Avg. Volume19,045
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)10.27
Price to Sales (P/S)8.28
P/FCF Ratio40.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe sharp revenue rebound indicates improved activity in the company’s development programs and provides a stronger base for future partnering or financing discussions, although the absolute revenue level remains modest for a clinical-stage biotechnology business.
Strong Gross MarginsStrong gross margins suggest that incremental revenue can contribute meaningfully toward research and corporate costs. If maintained, this supports the economics of future licensing or collaboration revenue as programs progress.
Improved Cash FlowThe return to positive operating and free cash flow is an important execution improvement after several years of cash burn. It may temporarily reduce reliance on external funding, provided cash generation does not reverse as development spending changes.
Bears Say
Persistent Net LossesContinued net losses show that the company has not yet established sustainable earnings power. Ongoing oncology development costs may keep the business dependent on financing or partnering proceeds until a program generates larger recurring economics.
High LeverageElevated leverage increases financial risk for a clinical-stage biotech whose income can be uncertain. Higher debt obligations can constrain research investment and reduce flexibility if additional capital is needed before development milestones are achieved.
Volatile Balance SheetLarge swings in equity and declining assets indicate limited balance-sheet resilience. This instability can make long-term program funding more difficult and increase dependence on new equity, debt, licensing, or other external financing.
Valerio Therapeutics News
0NWK FAQ
What was Valerio Therapeutics’s price range in the past 12 months?
Valerio Therapeutics lowest share price was €0.06 and its highest was €0.98 in the past 12 months.
What is Valerio Therapeutics’s market cap?
Valerio Therapeutics’s market cap is €386.00M.
When is Valerio Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Valerio Therapeutics’s earnings last quarter?
Currently, no data Available
Is Valerio Therapeutics overvalued?
According to Wall Street analysts Valerio Therapeutics’s price is currently Overvalued.
Does Valerio Therapeutics pay dividends?
Valerio Therapeutics does not currently pay dividends.
What is Valerio Therapeutics’s EPS estimate?
Valerio Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valerio Therapeutics have?
Valerio Therapeutics has 567,668,640 shares outstanding.
What happened to Valerio Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Valerio Therapeutics?
Currently, no hedge funds are holding shares in GB:0NWK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valerio Therapeutics
Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A. (known as Onxeo SA until June 2023) is a clinical-stage biotechnology company dedicated to the global research and development of oncology treatments. Their focus is on targeting the DNA repair processes crucial for tumor survival. The company's offerings include Beleodaq, an approved medication for peripheral T-cell lymphoma. Their development pipeline features AsiDNA, which is progressing through Phase 1 clinical trials for metastatic melanoma and is also being evaluated for relapsed ovarian cancer through a research collaboration with Gustave Roussy. Furthermore, Valerio Therapeutics is advancing OX401, a preclinical program targeting DNA damage response and immuno-oncology, along with its proprietary platON decoy oligonucleotide platform. The firm also holds a licensing agreement with Acrotech Biopharma LLC.
Technical Analysis
Innate Pharma SA
―
Transgene
―
OSE Immunotherapeutics SA
―
GenSight Biologics SA
―
Cellectis SA
―